Calidi Biotherapeutics Provides Required NYSE American Disclosure

Calidi Biotherapeutics disclosed that its 2025 annual financial statements include an audit report with a going concern explanatory paragraph, indicating substantial doubt about the company's ability to continue operations. The company is advancing its RedTail platform for genetic medicine delivery, with lead candidate CLD-401 in IND-enabling studies for cancer treatment.

05/22/2026, 6:00 PM • GlobeNewswire

Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics completed a $6.0 million underwritten public offering, selling 12.1 million shares of common stock along with Series J, K, and L warrants. Ladenburg Thalmann & Co. Inc. served as sole book-running manager. The warrants have exercise prices of $0.50 per share with varying expiration terms and include reset provisions.

03/09/2026, 8:50 PM • GlobeNewswire

Calidi Biotherapeutics Announces Proposed Public Offering

Calidi Biotherapeutics announced an underwritten public offering of units consisting of common stock and warrants, with Ladenburg Thalmann & Co. Inc. as sole book-running manager. The company intends to use net proceeds for working capital and general corporate purposes. The offering is subject to market conditions and there is no assurance as to completion timing or final terms.

03/05/2026, 5:57 PM • GlobeNewswire

Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

Calidi Biotherapeutics presented preclinical data on its RedTail virotherapy platform, which enables systemic delivery of bispecific T-cell engagers (BiTEs) and IL-15 superagonist directly to solid tumors. The approach aims to overcome BiTE limitations in solid tumors by remodeling the tumor microenvironment and activating T-cells. The company is conducting IND-enabling studies for CLD-401 and plans to submit an IND application by end of 2026.

02/20/2026, 8:00 AM • GlobeNewswire

Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

Calidi Biotherapeutics announced it will present data on its RedTail platform, a systemically delivered virotherapy designed to deliver BiTEs and IL-15 superagonist to solid tumors. The company is conducting IND-enabling studies for CLD-401, its lead candidate, with plans to submit an IND application by end of 2026. RedTail addresses the limitation of BiTEs in solid tumors by remodeling the tumor microenvironment to enable T-cell activation.

02/12/2026, 8:00 AM • GlobeNewswire

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

Calidi Biotherapeutics is hosting an investor webinar to discuss its RedTail platform, an engineered viral therapy designed to deliver genetic medicines to tumor sites. The company aims to advance its technology towards IND filing by end of 2026, targeting oncology markets projected to exceed $560 billion by 2033.

11/17/2025, 8:00 AM • GlobeNewswire

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Calidi Biotherapeutics completed a public offering, raising $6.9 million by selling common stock units and pre-funded warrant units, with Ladenburg Thalmann & Co. Inc. acting as sole book-running manager.

08/21/2025, 6:33 PM • GlobeNewswire

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Calidi Biotherapeutics will implement a 1-for-12 reverse stock split of its outstanding common stock, effective August 5, 2025, to optimize market dynamics and investor appeal.

07/25/2025, 4:45 PM • GlobeNewswire

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.

07/09/2025, 8:30 AM • Benzinga